Remove Clinic Remove Events Remove PET Scan
article thumbnail

PET predicts adverse events in heart disease patients

AuntMinnie

PET imaging with nitrogen-13 (N-13) ammonia radiotracer can help predict major adverse cardiac events in patients with ischemic heart disease (IHD), according to a study published May 30 in Radiology: Cardiothoracic Imaging. Patients underwent the scans between January 2017 and January 2021.

Disease 110
article thumbnail

Study validates diagnostic tool for identifying amyloid beta plaques, the hallmark of Alzheimer's disease

Medical Xpress: Radiology

Amyloid PET scans provide in-vivo evidence of Alzheimer's disease (AD) pathology. However, due to their high cost and limited insurance coverage, they are not widely used in clinical settings outside of the VA Healthcare System.

Disease 58
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AuntMinnie 2002: The Minnies 2002 final results

AuntMinnie

Welcome to the 2002 edition of the Minnies, AuntMinnie.com’ s annual event to recognize the best of radiology! Mayo Clinic, Jacksonville, FL MOST SIGNIFICANT NEWS EVENT IN RADIOLOGY 1. Increased use of medical imaging by other specialties (turf battles) HOTTEST CLINICAL PROCEDURE 1. Hybrid CT/PET scanning 2.

article thumbnail

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Imaging Technology

CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S. please insert video here.

article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

This event marks a major milestone in the expansion of Blue Earth Diagnostics’ robust prostate cancer portfolio. All of us at Blue Earth Diagnostics want to express our sincere gratitude to the many patients, physicians, clinical trial sites and collaborators who have worked closely with us to progress POSLUMA.” Gauden , D.Phil.,

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S.